Micelle BioPharma   Report issue

For profit Phase 2 Phase 3
Founded: Boca Raton FL United States (2004)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2013
NCT01997268
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Sancilio& Company, Inc

Active Ingredients

Drugs in Phase 3 Trials (2)

scopolamine (transderm scop) (1 trial)

succinylcholine (anectine) (1 trial)

Drugs in Phase 2 Trials (1)

fish oil (Omegavan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Hypertriglyceridemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3